Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study

Pyruvate kinase (PK) deficiency is the most common red cell glycolytic enzyme defect causing hereditary non-spherocytic hemolytic anemia. Current treatments are mainly supportive and include red cell transfusions and splenectomy.[1][1] Regular red cell transfusions are known to result in iron

• Publication year

  2018

• Venue

  Haematologica

• Publication date

  2018-09-13

• Fields of study

  Medicine

• Identifiers
  DOI 10.3324/haematol.2018.196295PMID 30213831PMCID PMC6355506
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study.

  2018cited by this paper
• Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions

  2015cited by this paper
• Erythrocyte pyruvate kinase deficiency: 2015 status report

  2015cited by this paper
• Iron-chelating therapy for transfusional iron overload.

  2011cited by this paper
• Iron-chelating therapy for transfusional iron overload.

  2011cited by this paper
• Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias

  2010cited by this paper
• Liver iron concentrations and urinary hepcidin in beta-thalassemia.

  2007cited by this paper
• Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload.

  2006cited by this paper

• Hereditary disorders of ineffective erythropoiesis.

  2025cites this paper
• Mitapivat (AG-348): a groundbreaking treatment paradigm for pyruvate kinase deficiency and beyond

  2024cites this paper
• Efficacy and Safety of Mitapivat in Pyruvate Kinase Deficiency: A Systematic Review and Meta-analysis of Clinical Trials

  2024cites this paper
• Flawed Value Assessment of Mitapivat to Manage Hemolytic Anemia in Adults With Pyruvate Kinase Deficiency

  2024cites this paper
• Comorbidities and complications in adult and paediatric patients with pyruvate kinase deficiency: Analysis from the Peak Registry

  2024cites this paper
• Pyruvate kinase deficiency in 29 Turkish patients with two novel intronic variants

  2024cites this paper
• Clinical and Demographic Characteristics of Pyruvate Kinase Deficiency Patients: A Comprehensive Case Series Analysis

  2024cites this paper
• Rare red cell enzymopathies in the indian population: A comprehensive review

  2024cites this paper
• Mitapivat: New dawn in pyruvate kinase deficiency and beyond

  2024cites this paper
• Diagnosis and management of pyruvate kinase deficiency: international expert guidelines.

  2024cites this paper
• Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency

  2024cites this paper
• The Pyruvate Kinase Deficiency Global Longitudinal (Peak) Registry: rationale and study design

  2023cites this paper
• Real-World Impact of Pyruvate Kinase Deficiency in Children

  2023cites this paper
• Pyruvate kinase activators for treatment of pyruvate kinase deficiency.

  2023cites this paper
• Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial

  2023influential citation
• Clinical outcome and genotype analysis of four Chinese children with pyruvate kinase deficiency

  2023cites this paper
• Association of PKLR gene copy number, expression levels and enzyme activity with 2,3,7,8-TCDD exposure in individuals exposed to Agent Orange/Dioxin in Vietnam.

  2023cites this paper
• Updates and advances in pyruvate kinase deficiency.

  2023cites this paper
• Iron overload disorders

  2022cites this paper
• Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (PKD)?: Toward an expanded definition of severe PKD

  2022cites this paper
• Circadian Redox Rhythm in Plant–Fungal Pathogen Interactions

  2022cites this paper
• A novel homozygous missense variant p.D339N in the PKLR gene correlates with pyruvate kinase deficiency in a Pakistani family: a case report

  2022cites this paper
• Pyruvatkinasemangel der Erythrozyten

  2022cites this paper
• Mitapivat versus Placebo for Pyruvate Kinase Deficiency.

  2022cites this paper
• Novel Compound Heterozygous PKLR Mutation Induced Pyruvate Kinase Deficiency With Persistent Pulmonary Hypertension in a Neonate: A Case Report

  2022cites this paper
• Proton pump inhibition for secondary hemochromatosis in hereditary anemia: a phase III placebo‐controlled randomized cross‐over clinical trial

  2022cites this paper
• Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial.

  2022cites this paper
• Pyruvate Kinase Deficiency: Current Challenges and Future Prospects

  2022cites this paper
• An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency

  2022cites this paper
• Pyruvatkinasemangel der Erythrozyten in Deutschland

  2021influential citation
• Consensus document for the diagnosis and treatment of pyruvate kinase deficiency.

  2021cites this paper
• Diagnosis and clinical management of enzymopathies.

  2021cites this paper
• Mitapivat, a novel pyruvate kinase activator, for the treatment of hereditary hemolytic anemias

  2021cites this paper
• Consensus document for the diagnosis and treatment of pyruvate kinase deficiency

  2021cites this paper
• From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox

  2021cites this paper
• Pyruvate kinase deficiency in children

  2021cites this paper
• Influence of transfusions, hemodialysis and extracorporeal life support on hyperferritinemia in critically ill patients

  2021cites this paper
• Diagnosis, monitoring, and management of pyruvate kinase deficiency in children

  2021cites this paper
• Laboratory approach to investigation of anemia with a focus on pyruvate kinase deficiency

  2020cites this paper
• The variable manifestations of disease in pyruvate kinase deficiency and their management.

  2020cites this paper
• Genotype‐phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency

  2020cites this paper
• Comorbidities and complications in adults with pyruvate kinase deficiency

  2020cites this paper
• Anémie hémolytique chronique dépendante de transfusions

  2020cites this paper
• A Family Affected by a Life-Threatening Erythrocyte Defect Caused by Pyruvate Kinase Deficiency With Normal Iron Status: A Case Report

  2020cites this paper
• Molecular heterogeneity of pyruvate kinase deficiency

  2020cites this paper
• The variable manifestations of disease in pyruvate kinase deficiency and their management

  2020cites this paper
• Molecular heterogeneity of pyruvate kinase deficiency.

  2020cites this paper
• Pyruvate kinase deficiency: epidemiology, molecular analyses and modern diagnostic approaches (literature review)

  2020cites this paper
• Management of Pyruvate Kinase Deficiency in Children and Adults.

  2020cites this paper
• Congenital Hemolytic Anemias: Is There a Role for the Immune System?

  2020cites this paper
• Successful allogeneic bone marrow transplantation using immunosuppressive conditioning regimen for a patient with red blood cell transfusiondependent pyruvate kinase deficiency anemia

  2020cites this paper
• Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation

  2019cites this paper
• Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency.

  2019cites this paper
• Development of the pyruvate kinase deficiency diary and pyruvate kinase deficiency impact assessment: Disease‐specific assessments

  2019cites this paper
• How we manage patients with pyruvate kinase deficiency

  2019cites this paper